Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ART0380 in advanced solid tumors with DNA repair defects
NCT05798611Phase 2Terminated
- Sponsor
- Artios Pharma
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of alnodesertib in endometrial cancer (EC), solid tumor, sponsored by Artios Pharma. Started Sep 2023; status: terminated.
02
Drugs
alnodesertib
03
Conditions
endometrial cancer (EC)solid tumor
Beyond the preview
Go deeper on NCT05798611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798611.